# J&J Therapy Adoption Analysis - Demo Guide

## Overview
This multi-agent AI system analyzes barriers to therapy adoption for Johnson & Johnson's major pharmaceutical products. The system uses three specialized AI agents that work together to provide comprehensive insights.

## The AI Team

### üîç Researcher Agent
- **Role**: Healthcare Market Intelligence
- **Capabilities**: 
  - Analyzes payer policies and insurance coverage
  - Researches competitive landscapes
  - Identifies market trends and prescriber behavior
  - Reviews clinical guidelines and utilization patterns

### üíª Coder Agent  
- **Role**: Financial & Data Analysis
- **Capabilities**:
  - Calculates ROI and revenue impact
  - Performs market share analysis
  - Computes denial rate impacts
  - Analyzes cost-benefit scenarios
  - Generates financial forecasts

### üéØ Manager Agent
- **Role**: Report Synthesis & Coordination
- **Capabilities**:
  - Coordinates researcher and coder agents
  - Synthesizes findings into actionable insights
  - Ensures comprehensive analysis
  - Produces executive-ready reports

## Available AI Models

You can select different models for each agent based on your needs:

- **GPT-4o** (Recommended) - Most capable, best for complex pharmaceutical analysis
- **GPT-4o Mini** - Fast and cost-effective for simpler queries
- **GPT-4 Turbo** - Previous generation, reliable and proven
- **GPT-3.5 Turbo** - Fastest option for straightforward calculations

## Pre-Loaded Analysis Scenarios

### 1. STELARA Adoption Barriers
**Focus**: Crohn's disease & ulcerative colitis
**Key Metrics**:
- 35% prescription rate (opportunity: 65% gap)
- 22% insurance denial rate
- $25K/year cost per patient
- 60% remission rate at 1 year

**Analysis Areas**:
- Insurance denial impact
- Cost barrier quantification  
- Prescriber awareness gaps
- Revenue recovery opportunities

### 2. DARZALEX Access Barriers
**Focus**: Newly diagnosed multiple myeloma
**Key Metrics**:
- 35K eligible patients annually
- 34% current adoption (12K patients)
- 18% denial rate with 14-day approval time
- +15% survival improvement vs standard care

**Analysis Areas**:
- Prior authorization delays
- Patient access impact
- Economic value of faster approvals
- Market expansion potential

### 3. ERLEADA Prostate Cancer Adoption
**Focus**: Non-metastatic castration-resistant prostate cancer
**Key Metrics**:
- 28K target patient population
- 30% market penetration (8,500 patients)
- 6-month average prescription lag
- $180K annual cost
- 41-month metastasis delay benefit

**Analysis Areas**:
- Prescription delay causes
- Revenue impact analysis
- Payer education ROI
- Clinical guideline alignment

### 4. TREMFYA Market Position
**Focus**: Moderate-to-severe plaque psoriasis
**Key Metrics**:
- $8.2B total biologics market
- 12% TREMFYA share ($984M)
- 73% PASI 90 efficacy at week 16
- 15% denial rate
- Competitors: Humira (28%), Cosentyx (22%), Skyrizi (18%)

**Analysis Areas**:
- Competitive differentiation
- Market share opportunity
- Denial rate optimization
- Investment requirements for growth

### 5. INVEGA SUSTENNA Adherence
**Focus**: Schizophrenia long-acting injectable
**Key Metrics**:
- 2.8M schizophrenia patients in US
- 18% LAI adoption vs 82% oral
- 150K INVEGA users
- 40% hospitalization reduction
- $15K/year hospitalization savings per patient
- 82% insurance approval rate

**Analysis Areas**:
- LAI adoption barriers (stigma, cost, inertia)
- Healthcare system savings potential
- Patient/prescriber education ROI
- Population health impact

### 6. Cross-Portfolio Denial Analysis
**Focus**: Insurance barriers across J&J portfolio
**Key Metrics**:
- $420M revenue at risk annually
- Denial rates: 15-25% across products
- 12-day average approval time
- 65% appeal success rate

**Analysis Areas**:
- Which therapy has highest denial impact
- Revenue recovery strategies
- Prior auth support team ROI
- Payer engagement priorities

## How to Use

### Starting the Demo

1. **Open the application**: http://localhost:3000
2. **Select AI models** for each agent (or use defaults)
3. **Choose a scenario** by clicking an example card
4. **Click "Execute with AI Team"** to start analysis
5. **Watch the Activity Log** to see real-time agent collaboration
6. **Review the comprehensive report** with insights and recommendations

### Custom Analysis

You can also create custom queries. Include:

1. **Context**: Therapy name, indication, patient population
2. **Current Metrics**: Adoption rates, costs, denial rates, clinical data
3. **Specific Questions**: ROI calculations, barrier identification, market opportunities

Example custom query:
```
Analyze adoption barriers for [THERAPY NAME] in [INDICATION]:

Current situation:
- Patient population: [NUMBER]
- Current adoption: [PERCENTAGE]
- Denial rate: [PERCENTAGE]
- Cost: [AMOUNT]
- Clinical benefit: [DESCRIPTION]

Questions:
1. What is the primary barrier: cost, insurance, or awareness?
2. Calculate revenue opportunity if adoption increases by [X]%
3. ROI analysis for [SPECIFIC INTERVENTION]
```

## Interpreting Results

### Activity Log
- **üéØ Manager**: Task coordination and workflow planning
- **üîç Researcher**: Market intelligence gathering (watch for "gathered X research data points")
- **üíª Coder**: Financial calculations (watch for "performed X mathematical operations")
- **üìä Summary**: Final collaboration overview

### The Report

Reports typically include:

1. **Executive Summary**: Key findings and recommendations
2. **Barrier Analysis**: Primary and secondary adoption obstacles
3. **Financial Impact**: Revenue opportunities, cost-benefit analysis
4. **Quantitative Analysis**: ROI calculations, market projections
5. **Recommendations**: Prioritized action items

## Real Data Used

The scenarios include realistic pharmaceutical metrics:
- Industry-standard adoption rates
- Typical insurance denial patterns
- Real-world therapy costs
- Clinical trial efficacy data
- Market share distributions
- Healthcare cost savings

## Demo Tips

### For Executive Presentations:
- Start with STELARA or DARZALEX (clear barriers, strong data)
- Emphasize the "X mathematical operations" and "Y research data points" in activity log
- Highlight revenue recovery opportunities ($XXM)

### For Clinical/Medical Teams:
- Focus on ERLEADA or INVEGA (clinical benefit emphasis)
- Show how AI synthesizes clinical + financial data
- Demonstrate evidence-based recommendations

### For Market Access/Payer Relations:
- Use Cross-Portfolio Denial Analysis
- Compare denial rate impacts across products
- Calculate ROI of payer engagement programs

### For Strategic Planning:
- TREMFYA competitive analysis
- Market share opportunity calculations
- Investment requirement analyses

## Technical Notes

- **Response Time**: 30-60 seconds depending on complexity
- **Model Selection**: GPT-4o recommended for most accurate pharmaceutical analysis
- **Activity Logging**: Real-time visibility into agent thought processes
- **Data Privacy**: All analysis runs on your Azure infrastructure
- **Scalability**: Can analyze multiple therapies simultaneously

## Next Steps

After the demo:
1. Discuss integrating real J&J proprietary data
2. Customize scenarios for specific therapeutic areas
3. Add more agents (e.g., Regulatory Affairs, Medical Affairs)
4. Connect to internal data sources (sales, claims, clinical)
5. Deploy to production with appropriate security controls

## Support

For questions about:
- **Setup**: Check backend logs at c:\E2EDemo\backend_debug.log
- **Custom Scenarios**: Modify examples in magentic_ui_backend.py
- **Model Performance**: Try different models for each agent
- **Integration**: agent_framework documentation

---

**Powered by**: Azure OpenAI (GPT-4o) + Agent Framework + CopilotKit
